Literature DB >> 26239522

Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies.

David J Greenblatt1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239522     DOI: 10.1002/jcph.609

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  5 in total

1.  Genotoxicity of pyrrolizidine alkaloids in metabolically inactive human cervical cancer HeLa cells co-cultured with human hepatoma HepG2 cells.

Authors:  Naji Said Aboud Hadi; Ezgi Eyluel Bankoglu; Helga Stopper
Journal:  Arch Toxicol       Date:  2022-10-23       Impact factor: 6.168

2.  Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.

Authors:  Takao Yamazaki; Amit Desai; David Han; Kota Kato; Donna Kowalski; Shahzad Akhtar; Christopher Lademacher; Laura Kovanda; Robert Townsend
Journal:  Clin Pharmacol Drug Dev       Date:  2016-07-20

3.  Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength.

Authors:  Eric R Samuels; Irina F Sevrioukova
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

4.  Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.

Authors:  Mark J Ratain; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2022-05-05       Impact factor: 2.860

5.  Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.

Authors:  Jahnavi Kharidia; Eleanor M Howgate; Celine M Laffont; Yongzhen Liu; Malcolm A Young
Journal:  Clin Pharmacol Drug Dev       Date:  2021-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.